Johnson & Johnson
JNJ Healthcare Drug Manufacturers General
Johnson & Johnson’s revenue for fiscal 2025 (year ended December 2025) was $94.2 billion, up 6.05% from fiscal 2024. In the quarter to September 2026, revenue grew 5.86%, EPS was flat, free cash flow grew 154.8% and total debt fell 4.82%, each against the same quarter a year earlier. Member of the S&P 500 and Dow Jones; dividend growth for twenty-five consecutive years, revenue growth for three, operating cash flow growth for three; insiders bought in the last twelve months.
Follow JNJ
Johnson & Johnson (JNJ) Shares outstanding
Johnson & Johnson's shares outstanding at the end of fiscal 2025 was $2.4B, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was $2.4B. Over the past ten years it has ranged from $2.4B (fiscal 2025) to $2.8B (fiscal 2015) — the current reading is the lowest in ten years. Johnson & Johnson ranks 4th of 20 Drug Manufacturers General companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $2.4B | 0.00% |
| FY2024 | $2.4B | (5.12%) |
| FY2023 | $2.6B | (3.89%) |
| FY2022 | $2.7B | (0.38%) |
| FY2021 | $2.7B | 0.12% |
| FY2020 | $2.7B | (0.51%) |
| FY2019 | $2.7B | (1.63%) |
| FY2018 | $2.7B | (0.60%) |
| FY2017 | $2.7B | (1.56%) |
| FY2016 | $2.8B | (0.85%) |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $2.4B | 0.35% |
| Jun 2026 | $2.4B | (0.21%) |
| Mar 2026 | $2.4B | 0.65% |
| Dec 2025 | $2.4B | 0.03% |
| 43 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| PFE Pfizer Inc. compare | $5.7B |
| MRK Merck & Co., Inc. compare | $2.5B |
| JNJ Johnson & Johnson | $2.4B |
| NVS Novartis AG compare | $1.9B |
| ABBV AbbVie Inc. compare | $1.8B |
| AZN AstraZeneca PLC compare | $1.6B |
| GILD Gilead Sciences, Inc. compare | $1.2B |
| LLY Eli Lilly and Company compare | $893.7M |
| AMGN Amgen Inc. compare | $544.0M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on JNJ
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement